Novapyrin

End insulin-dependent diabetes with antioxidants. The two antioxidants that need to be taken twice daily are pyrroloquinoline quinone (PQQ 10 mg) and N-acetylcysteine (NAC, 600 mg). For convenience we propose to put these dietary supplements in one gelcap and make it available under the trade name Novapyrin.

Insulin-dependent diabetes can be prevented by attenuating the innate complement system by creating a reactive oxygen radical free state by simply taking pyrroloquinoline quinone (PQQ 10 mg) and N-acetylcysteine NAC (600 mg) twice daily. 

As PQQ is not available worldwide, the introduction of our low-cost formulation will lead to the eradication of insulin-dependent diabetes.

Insulin-dependent diabetes is a severe chronic condition which costs patients ~USD 1000/month to treat. The inconvenience of daily blood glucose monitoring and cost of the insulin to achieve near normoglycaemia are eliminated by eliminating the disease rather than treating it with insulin.

We observed in a volunteer on PQQ/NAC therapy reversal of the metabolic syndrome.  

The elimination of insulin dependent diabetes will improve patient well being and unburden them of great expense. At present a one month expense of blood glucose monitoring reagents and for insulin are in the range of USD 1000. All insulin dependent diabetics will profit from it. The national health care budget will save significantly. 

- Number of insulin-dependent diabetic patients as reported by CDC

To the best of our knowledge there exist no therapy to prevent and reverse insulin-dependent diabetes.

Our nutritional formulation Novapyrin will become available worldwide.

Our finding and the underlying science will be published in a peer-reviewed publication. As one of the constituents (PQQ) is not available worldwide but Novapyrin will be it will be accessible to all.

We are retired and do not need salary income. The product has been developed and tested. Novapyrin will be sold at cost plus handling and shipping costs. 

The manufacture of our product has been priced by Private Label but we lack the capital for its manufacture of USD90,000.

In order to implement our solution we need seed capital which we hope Solve will help us find.

We have no partners. There is no conflict of interest. All expenses were paid out of pocket which leaves us without capital to produce our product.

There are no competitors